UGN

Experience Rick partners with UVS Games to Elevate the My Hero Academia CCG Experience with #RumbleRama!

Retrieved on: 
Thursday, September 28, 2023
Universe, UVS, My Hero Academia, UGN, Environment, MHA, Entertainment

To bring even more excitement to the MHA CCG community, Experience Rick is collaborating with UVS Games, the creators of the My Hero Academia CCG.

Key Points: 
  • To bring even more excitement to the MHA CCG community, Experience Rick is collaborating with UVS Games, the creators of the My Hero Academia CCG.
  • Together, they're introducing thrilling opportunities for players to engage in epic battles, forge new friendships, and flourish in the vibrant world of My Hero Academia.
  • Whether you're a battle-hardened MHA CCG veteran or just starting a heroic journey, #RumbleRama promises something extraordinary for everyone.
  • ExperienceRick and UVS Games are creating a welcoming and inclusive environment where players of all skill levels can come together to enjoy the game.

From Shirts to Insulators: Recycled Honda Uniforms Find New Utility in Vehicles

Retrieved on: 
Thursday, August 10, 2023
Triple Action, Aramark, Culture, Cintas, PET, UGN, Carbon, Recycling, History, American Honda Motor Company, Insulator, Geier v. American Honda Motor Co., Element, RDX, Formula One Teams Association, Automotive industry, Renewable energy, Acura

Honda is working toward its resource circulation goal of making new products from 100% sustainable materials by 2050.

Key Points: 
  • Honda is working toward its resource circulation goal of making new products from 100% sustainable materials by 2050.
  • Achieving that goal – which targets zero environmental impact – will require innovative solutions, including how Honda sources materials for new products by recycling and reusing material from end-of-life vehicles and Honda operations.
  • "As Honda works to advance sustainability, we appreciate our suppliers' efforts to innovate their business operations to reduce waste and give new life to our Honda uniforms."
  • The uniform recycling program builds on Honda's longstanding commitment to reduce waste and incorporate higher recycled content in Honda and Acura vehicles.

SP Publishes Updated Carbon Reduction & Reporting Guidance with Support of Leading Automotive Suppliers

Retrieved on: 
Wednesday, December 14, 2022
Carbon, Magna International, General Motors, US, UGN, CO2, Tier 1, SP, Stellantis, Multimedia, Magna, Toyota Motor North America, DENSO, OEM, Environment, Lear Corporation, Ford Motor Company, Carbon dioxide, Renewable energy, Risk management, Sustainability

WASHINGTON, Dec. 14, 2022 /PRNewswire/ -- The Suppliers Partnership for the Environment (SP) today published an updated version of the guidance document, " Carbon Reduction KPIs, Terms & Definitions ," with the additional support of several leading Tier 1 automotive suppliers.

Key Points: 
  • WASHINGTON, Dec. 14, 2022 /PRNewswire/ -- The Suppliers Partnership for the Environment (SP) today published an updated version of the guidance document, " Carbon Reduction KPIs, Terms & Definitions ," with the additional support of several leading Tier 1 automotive suppliers.
  • As companies in the automotive industry proactively work toward long-term goals of achieving carbon neutrality, it is expected that suppliers take an active role in striving to reduce carbon dioxide (CO2) emissions from their businesses as far as possible.
  • The purpose of this document is to provide general industry-supported guidance to help companies in the automotive value chain in establishing a framework for CO2 reporting and reduction aligned with common industry expectations.
  • This guidance provides us with a solid foundation on common industry expectations and ways to standardize progress on carbon reduction and reporting.

Romeo Power Announces Appointments to Key Executive Leadership Roles

Retrieved on: 
Tuesday, January 18, 2022
Other Energy, Technology, Environment, Other Technology, Alternative Energy, Energy, People, Romeo, Forward-looking statement, Technology, UGN, University, Business administration, Rogers, SEC, CPO, COO, Bachelor of Science in Information Technology, NYSE, Safety, Growth, Ducommun, Kettering University, Leadership, Stephenson Disaster Management Institute, EV, Industry, Culture, Ecosystem, Private Securities Litigation Reform Act, Company, California State University, Original equipment manufacturer, GMI, Cell, Organization, Acquisition, Management, Engineering, COVID-19, Science, Rose Rogers, Anne Devine, Romeo Power, Inc., ROSE ROGERS, ANNE DEVINE, ROMEO POWER, INC.

Ms. Devine will replace Criswell Choi, who will leave Romeo after a four-week transition period to pursue other opportunities.

Key Points: 
  • Ms. Devine will replace Criswell Choi, who will leave Romeo after a four-week transition period to pursue other opportunities.
  • Over the last several months we have transformed our leadership, and Im thrilled to add two more high-profile executives to our team here at Romeo Power.
  • Prior to joining Romeo Power, Ms. Rogers served as the Vice President and Chief Human Resources Officer at Ducommun Incorporated in Santa Ana, California.
  • To keep up with everything Romeo Power, please follow the Company on social @romeopowerinc or visit https://romeopower.com .

XTM Appoints Finance Executive Randy Khalaf to Board of Directors

Retrieved on: 
Friday, May 21, 2021
Payment cards, Credit cards, Money, Finance, Debit cards, Online payments, GKN, MasterCard, Visa Inc., UGN

Khalaf is recognized for his busines acumen and success in growing EBITDA, overseeing operations, and leading global finance across several companies including UGN Incorporated based in Tinley Park, IL and GKN Driveline of Auburn Hills, MI.\n"We welcome Randy to the Board and look forward to his participation," said Marilyn Schaffer, CEO.

Key Points: 
  • Khalaf is recognized for his busines acumen and success in growing EBITDA, overseeing operations, and leading global finance across several companies including UGN Incorporated based in Tinley Park, IL and GKN Driveline of Auburn Hills, MI.\n"We welcome Randy to the Board and look forward to his participation," said Marilyn Schaffer, CEO.
  • "\nPaul Haber has resigned from the board.
  • XTM integrates businesses to a payment ecosystem that is coupled with a free mobile app and a Visa or Mastercard debit card with free banking features.
  • All such forward-looking statements are based on the opinions and estimates of management as of the date such statements are made.

Complete and Durable Responses Observed in OPTIMA II Phase 2b Final Results for UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer

Retrieved on: 
Tuesday, November 17, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Organic compounds, Chemical compounds, Infectious causes of cancer, Aziridines, Carbamates, Enones, Quinones, Chemistry, Bladder cancer, Mitomycins, Cancer, UGN, the Phase 2b OPTIMA II Trial, UGN-102

As previously reported, 65% (41/63) of patients receiving UGN-102 achieved a complete response (CR) three months after the start of therapy.

Key Points: 
  • As previously reported, 65% (41/63) of patients receiving UGN-102 achieved a complete response (CR) three months after the start of therapy.
  • The Company expects to initiate a Phase 3 study evaluating UGN-102 versus current standard of care by the end of the year.
  • The current approach to treating patients diagnosed with low-grade intermediate risk non-muscle invasive bladder cancer is surgery.
  • UGN-102 (mitomycin) for intravesical solution is an investigational drug formulation of mitomycin in Phase 2b development for the treatment of low-grade intermediate risk non-muscle invasive bladder cancer.

UroGen Pharma Reports Third Quarter 2019 Financial Results and Recent Corporate Developments

Retrieved on: 
Tuesday, November 12, 2019
Health, FDA, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Articles, Life sciences, Fast track, Food and Drug Administration, UGN, Cash and cash equivalents, Pharmaceutical industry

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced financial results for the third quarter ended September 30, 2019 and provided an overview of the Companys recent developments.

Key Points: 
  • UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced financial results for the third quarter ended September 30, 2019 and provided an overview of the Companys recent developments.
  • The FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to UGN-101 for the treatment of LG UTUC.
  • UroGen recently presented interim results from the single-arm, open-label Phase 2b OPTIMA II trial of investigational UGN-102 for patients with intermediate risk LG NMIBC.
  • Third Quarter 2019 Financial Results; 2019 Guidance
    As of September 30, 2019, cash, cash equivalents and marketable securities totaled $221.7 million.

UroGen Investor Day Details Positive Clinical Updates, UGN-101 Launch Preparedness, and Pipeline Advances

Retrieved on: 
Tuesday, September 24, 2019
Biotechnology, Pharmaceutical, Oncology, Health, Clinical trials, Other Health, UGN, UGN-101, UGN-102, UroGen Pharma Ltd.

At UroGen, we are 100 percent committed to overcoming obstacles that have stunted much needed innovation in uro-oncology, said Liz Barrett, President and Chief Executive Officer of UroGen.

Key Points: 
  • At UroGen, we are 100 percent committed to overcoming obstacles that have stunted much needed innovation in uro-oncology, said Liz Barrett, President and Chief Executive Officer of UroGen.
  • While we prepare for a potential launch of UGN-101, we believe this is just the beginning of what is possible with our pipeline.
  • Durability of response determined to be 89 percent at six months and 84 percent at twelve months.
  • Rolling NDA submission is on track for Q4 2019 with potential approval and launch in 1H 2020.

UroGen Delivers Updated Complete Response (CR) and Durability Data from the UGN-101 Phase 3 OLYMPUS Trial

Retrieved on: 
Sunday, May 5, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Other Health, UGN, United Trade Union Congress

The results from the OLYMPUS trial continue to be compelling for new and recurrent LG UTUC, as well as for those who have unresectable tumors and would be immediate candidates for kidney removal.

Key Points: 
  • The results from the OLYMPUS trial continue to be compelling for new and recurrent LG UTUC, as well as for those who have unresectable tumors and would be immediate candidates for kidney removal.
  • The analysis also advances our understanding of durability of response, which we are pleased to see has remained consistent as the number of patients who reach the six-month follow-up timepoint increases.
  • The FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to UGN-101 for the treatment of UTUC.
  • Patients who achieved a complete response at the PDE timepoint were then followed for up to 12 months to determine the durability of disease control with UGN-101.

UroGen Pharma Announces Presentation of Analysis from Phase 3 OLYMPUS Trial of UGN-101 for Patients with Low-Grade Upper Tract Urothelial Cancer

Retrieved on: 
Friday, April 5, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, FDA, Pharmacology, Organic compounds, Health, Aziridines, Carbamates, Quinones, Carcinoma, Transitional cell carcinoma, Mitomycins, UGN, United Trade Union Congress, Transitional epithelium

UroGen is committed to raising the standard of care for this typically elderly patient population whose current options consist of repetitive endoscopic surgical intervention or complete loss of a kidney.

Key Points: 
  • UroGen is committed to raising the standard of care for this typically elderly patient population whose current options consist of repetitive endoscopic surgical intervention or complete loss of a kidney.
  • We look forward to presenting this UGN-101 analysis that further underscores the unmet need in patients with new and recurrent LG UTUC.
  • UGN-101 (mitomycin gel) for instillation is an investigational drug formulation of mitomycin in Phase 3 development for the treatment of low-grade upper tract urothelial cancer (LG UTUC).
  • UroGen has developed RTGel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs.